Business

BioNano Genomics Inc (NASDAQ: BNGO) Provides Diagnostic Testing

BioNano Genomics Inc (NASDAQ: BNGO) announced the reviewed studies by two peers from well-known clinicians and scientists from European Institutions, including Hospices Civils in Lyon, Radboud University Medical Center, the University Hospital of Clermont-Ferrand, Radboud University Medical Center was published in the American Journal of Human Genetics back-to-back.

Two groups reviewed OGM: One group analyzed the genomes with genetic diseases inherited, while other groups studied haematological malignancies. The study states the utility of OGM (Optical Genome Mapping), superior compared to the traditional methods for SV (Structural Variant) analysis. The study reveals OGM is 100% in line with karyotype, fluorescent in-situ hybridization (FISH), and CNV-microarray. The study further reveals that the utility of OGM also reveals the detection of more minor cancer-associated events that usually get escape by traditional means.

OGM-One of the best alternatives: As per the report submitted by both the groups, it is found that Optical Genome Mapping provides a supplement to existing sequencing-based methods for genome variation. In addition, OGM also has the potential to become a primary analysis for molecular cytogenetics applications. The scientists and clinicians who reviewed the reports stated that OGM is one of the best alternatives for inherited genetic and haematological malignancy applications. Additionally, they also stated that the workflow of OGM could be easily analyzed by the laboratory, which is of vital importance. Hence, it is different from sequencing-based methods, which require solid analytical pipelines and expertise to analyze the data. 

As per the various specialist doctors, it is stated that OGM is a massive breakthrough since the CNV-microarray. OGM is one of the methods whose outcome is promising and can be studied easily. It is believed that OGM can replace traditional cytogenetics in hematologic malignancies and genetic diseases. The innovation is just the start and has a long way to go, and it is expected that these developments have led to efficient workflows with better health outcomes.

Leave a Comment

Your email address will not be published.

*